RxSight Gets Downgrade as Future Performance Seen With Uncertainty -- Market Talk
Dow Jones
Jul 09, 2025
9:44 ET -- RxSight gets a downgrade from Wells Fargo after what it described as another disappointing quarter. The ophthalmic medical device company on Tuesday guided for a decline in 2Q revenue and lowered its full-year revenue guidance. "While we still view the technology favorably, we misjudge the structural issues facing RxSight, and based on the guidance update, we are now uncertain about future performance," the analysts say. Wells Fargo sets a rating of equal weight and price target of $9 compared to a prior rating of $25 and price target of $25. Shares are 49% lower at $6.46 in premarket trading. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
July 09, 2025 09:44 ET (13:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.